| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Zheng-Xing Su, Ya-Nan Shi, Le-Sheng Teng, Xiang Li, Le-xi Wang, Qing-Fan Meng, Li-Rong Teng, You-Xin L. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Pharmaceutical development and technology. vol 16. issue 4. 2012-02-10. PMID:20370594. |
the preparation and investigation of sustained-release risperidone-encapsulated microspheres using erodible poly(d, l-lactide-co-glycolide) (plga) of lower molecular weight were performed and compared to that of commercial risperdal consta™ for the treatment of schizophrenia. |
2012-02-10 |
2023-08-12 |
Not clear |
| Takatoshi Mor. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 113. issue 10. 2012-02-09. PMID:22187885. |
[case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. |
2012-02-09 |
2023-08-12 |
Not clear |
| Takatoshi Mor. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 113. issue 10. 2012-02-09. PMID:22187885. |
i report a case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection (rlai). |
2012-02-09 |
2023-08-12 |
Not clear |
| Jason Jonathon Sico, Huned Patw. Risperidone-induced bulbar palsy-like syndrome. Dysphagia. vol 26. issue 3. 2012-02-08. PMID:20922432. |
we report on a 58-year-old gentleman with prior history of schizophrenia and remote chlorpromazine use with no history of extrapyramidal symptoms who experienced acute onset of dysphagia and facial diplegia with hyperprolactinemia while being treated with risperidone. |
2012-02-08 |
2023-08-12 |
Not clear |
| George Bartzokis, Po H Lu, Chetan P Amar, Erika P Raven, Nicole R Detore, Lori L Altshuler, Jim Mintz, Joseph Ventura, Laurie R Casaus, John S Luo, Kenneth L Subotnik, Keith H Nuechterlei. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophrenia research. vol 132. issue 1. 2012-01-24. PMID:21767934. |
long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. |
2012-01-24 |
2023-08-12 |
human |
| Jennifer Kern Sliwa, Cynthia A Bossie, Yi-Wen Ma, Larry Alph. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophrenia research. vol 132. issue 1. 2012-01-24. PMID:21775106. |
effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. |
2012-01-24 |
2023-08-12 |
human |
| Jennifer Kern Sliwa, Cynthia A Bossie, Yi-Wen Ma, Larry Alph. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophrenia research. vol 132. issue 1. 2012-01-24. PMID:21775106. |
to examine efficacy and safety of acute treatment with paliperidone palmitate in subjects with schizophrenia whose disease remained symptomatic despite recent treatment with oral risperidone. |
2012-01-24 |
2023-08-12 |
human |
| Nam Young Lee, Se Hyun Kim, Dong Chung Jung, Eun Young Kim, Han Young Yu, Ki Hye Sung, Ung Gu Kang, Yong Min Ahn, Yong Sik Ki. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 5. 2012-01-19. PMID:21513765. |
the prevalence of metabolic syndrome in korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. |
2012-01-19 |
2023-08-12 |
Not clear |
| Nam Young Lee, Se Hyun Kim, Dong Chung Jung, Eun Young Kim, Han Young Yu, Ki Hye Sung, Ung Gu Kang, Yong Min Ahn, Yong Sik Ki. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 5. 2012-01-19. PMID:21513765. |
we reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months. |
2012-01-19 |
2023-08-12 |
Not clear |
| Nam Young Lee, Se Hyun Kim, Dong Chung Jung, Eun Young Kim, Han Young Yu, Ki Hye Sung, Ung Gu Kang, Yong Min Ahn, Yong Sik Ki. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 5. 2012-01-19. PMID:21513765. |
in conclusion, only male korean patients with schizophrenia who received a monotherapy of aripiprazole, olanzapine or risperidone for more than three months were more likely to have mets than the general population. |
2012-01-19 |
2023-08-12 |
Not clear |
| Xiaofeng Guo, Jinguo Zhai, Qinling Wei, Elizabeth W Twamley, Hua Jin, Maosheng Fang, Maorong Hu, Jingping Zha. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neuroscience letters. vol 503. issue 2. 2012-01-13. PMID:21888948. |
in a 12-month, open-label, multicenter study, 698 patients with early-stage schizophrenia (duration of illness ≤5 years) were prescribed chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole monotherapy. |
2012-01-13 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Norio Sugawara, Akira Fujii, Sunao Kanek. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone. Journal of clinical psychopharmacology. vol 31. issue 5. 2011-12-27. PMID:21869689. |
sixty patients with acute exacerbations of schizophrenia received 6 mg/d of risperidone for 4 weeks. |
2011-12-27 |
2023-08-12 |
Not clear |
| Neil M Richtand, Rebecca Ahlbrand, Paul Horn, Kevin Stanford, Stefanie L Bronson, Robert K McNamar. Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. Journal of psychiatric research. vol 45. issue 9. 2011-12-23. PMID:21440257. |
we aimed to extend those findings evaluating risperidone and paliperidone following prenatal immune activation, a developmental model of a schizophrenia risk factor. |
2011-12-23 |
2023-08-12 |
Not clear |
| Vicente Molina, Carmen Martín, Alejandro Ballesteros, Alba G Seco de Herrera, Juan Antonio Hernández-Tamame. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. European archives of psychiatry and clinical neuroscience. vol 261. issue 6. 2011-12-21. PMID:21191610. |
to this end, in this study, magnetic resonance imaging (mri) and voxel-based morphometry (vbm) were used to assess the relationship between the brain volumes of gray (gm) and white (wm) matters and the clinical response to risperidone or olanzapine in 30 schizophrenia patients. |
2011-12-21 |
2023-08-12 |
Not clear |
| Vicente Molina, Carmen Martín, Alejandro Ballesteros, Alba G Seco de Herrera, Juan Antonio Hernández-Tamame. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. European archives of psychiatry and clinical neuroscience. vol 261. issue 6. 2011-12-21. PMID:21191610. |
this study reveals a pattern of structural alterations in schizophrenia associated with the response to risperidone or olanzapine. |
2011-12-21 |
2023-08-12 |
Not clear |
| Kun Kim, Eline Aa. Cost-effectiveness analysis of olanzapine and risperidone in Norway. The journal of mental health policy and economics. vol 14. issue 3. 2011-12-20. PMID:22116170. |
antipsychotic medications are the mainstay for schizophrenia treatment, and olanzapine and risperidone are popular choices among atypical antipsychotics in norway. |
2011-12-20 |
2023-08-12 |
Not clear |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
a double-blind, placebo-controlled study of traditional chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
objective to identify whether sarsasapogenin, a sapogenin from the chinese medicinal herb anemarrhena asphodeloides bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
conclusion sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |
| Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan, Ming-Yuan Zhan. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neuroscience bulletin. vol 27. issue 4. 2011-12-06. PMID:21788997. |
sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia. |
2011-12-06 |
2023-08-12 |
human |